SCHEMBL918632

SCHEMBL918632

CC1CCC(NCCCS(=O)(=O)O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 2/20 0.36
S1PR1 P21453 2/20 0.36
S1PR3 Q99500 2/20 0.36
ALDH1A1 P00352 4/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 3/20 0.35
GNAI3 P08754 2/20 0.35
GNAO1 P09471 2/20 0.35
GNAI1 P63096 2/20 0.35
POLB P06746 1/20 0.35
RECQL P46063 1/20 0.35
KDM4E B2RXH2 2/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
EPHX1 P07099 1/20 0.34
APP P05067 1/20 0.33
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
SQLE Q14534 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17923284 0.96 S1PR4 (0.36) S1PR4S1PR1S1PR3ALDH1A1RAB9A
SCHEMBL917789 0.91 APP (0.39) S1PR4S1PR1S1PR3ALDH1A1GNAI3
SCHEMBL21518353 0.87 APP (0.39) S1PR4S1PR1S1PR3ALDH1A1GNAI3
SCHEMBL11807435 0.85 S1PR4 (0.43) S1PR4S1PR1S1PR3ALDH1A1RAB9A
SCHEMBL918238 0.83 S1PR4 (0.41) S1PR4S1PR1S1PR3ALDH1A1GNAI3
SCHEMBL918520 0.83 CXCR4 (0.44) S1PR4S1PR1S1PR3ALDH1A1KDM4E
SCHEMBL11516269 0.82 APP (0.38) S1PR4S1PR1S1PR3GNAI3GNAO1
SCHEMBL37872 0.81 CXCR4 (0.46) ALDH1A1KDM4EEPHX1CA12CXCR4
SCHEMBL21518374 0.81 CXCR4 (0.46) ALDH1A1KDM4EEPHX1CA12CXCR4
SCHEMBL918578 0.81 CXCR4 (0.46) ALDH1A1KDM4EEPHX1CA12CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4190832-B1 POLYISOCYANATE COMPOSITION, COATING COMPOSITION AND COATED SUBSTRATE ASAHI CHEMICAL IND (JP) 2026-04-08 EP disclosed
US-12559453-B2 Sulfonic acid-modified polyisocyanate and preparation method therefor WANHUA CHEMICAL GROUP CO., LTD. (CN) 2026-02-24 US disclosed
EP-4144780-B1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR WANHUA CHEMICAL GROUP CO LTD (CN) 2025-12-24 EP disclosed
EP-3878838-B1 POLYISOCYANATE COMPOSITION, COATING COMPOSITION AND COATED SUBSTRATE ASAHI CHEMICAL IND (JP) 2025-07-23 EP disclosed
CN-120059105-A Polyisocyanate composition, coating composition and coated substrate 旭化成株式会社 2025-05-30 CN disclosed
EP-4332137-A1 BASE COATING COMPOSITION, MULTILAYER COATING FILM LAMINATE, AND METHOD FOR FORMING MULTILAYER COATING FILM LAMINATE Asahi Kasei Kabushiki Kaisha (JP) 2024-03-06 EP disclosed
CN-117645828-A Coating composition for substrate, multilayer coating film laminate, and method for forming multilayer coating film laminate 旭化成株式会社 2024-03-05 CN disclosed
CN-117264175-A Polyisocyanate composition, aqueous coating composition, coated substrate, and method for producing polyisocyanate composition 旭化成株式会社 2023-12-22 CN disclosed
EP-4293060-A1 POLYISOCYANATE COMPOSITION, BLOCKED POLYISOCYANATE COMPOSITION, POLYURETHANE RESIN COMPOSITION, COATING COMPOSITION AND COATING SUBSTRATE Asahi Kasei Kabushiki Kaisha (JP) 2023-12-20 EP disclosed
CN-117229476-A Polyisocyanate composition, blocked polyisocyanate composition, polyurethane resin composition, coating composition, and coated substrate 旭化成株式会社 2023-12-15 CN disclosed
US-7253306-B2 Pharmaceutical drug candidates and methods for preparation thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-08-07 US disclosed
US-7253306-B2 Pharmaceutical drug candidates and methods for preparation thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-08-07 US disclosed
US-7253306-B2 Pharmaceutical drug candidates and methods for preparation thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-08-07 US disclosed
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2007-01-11 US disclosed
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2007-01-11 US disclosed
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2007-01-11 US disclosed
EP-1644325-A2 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES Neurochem (International) Limited (CH) 2006-04-12 EP disclosed
US-20050143462-A1 Pharmaceutical drug candidates and methods for preparation thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-06-30 US disclosed
US-20050096385-A1 Methods and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2005-05-05 US disclosed
WO-2004113275-A2 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559453-B2 Sulfonic acid-modified polyisocyanate and preparation method therefor TMT1A, SRMS, FTO S1PR4 4179/4885S1PR1 4135/4885S1PR3 4467/4885
US-20050143462-A1 Pharmaceutical drug candidates and methods for preparation thereof MPST, TTR, STS S1PR4 1075/4885S1PR1 393/4885S1PR3 418/4885
US-20050096385-A1 Methods and compositions for treating amyloid-related diseases APP, PSEN1, PSEN2 S1PR4 3981/4885S1PR1 3406/4885S1PR3 3633/4885
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases APP, PSEN1, PSEN2 S1PR4 3981/4885S1PR1 3406/4885S1PR3 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.